N
OVID icon

Nuveen’s Ovid Therapeutics OVID Stock Holding History

Nuveen’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-119,113
Closed -$37.2K – 3371
2025
Q1 		$37.2K Hold
119,113
– – ﹤0.01% 3270
2024
Q4 		$111K Hold
119,113
– – ﹤0.01% 3279
2024
Q3 		$141K Hold
119,113
– – ﹤0.01% 3279
2024
Q2 		$91.6K Hold
119,113
– – ﹤0.01% 3310
2024
Q1 		$363K Buy
119,113
+5,028
+4% +$16.8K ﹤0.01% 3057
2023
Q4 		$367K Hold
114,085
– – ﹤0.01% 3100
2023
Q3 		$438K Hold
114,085
– – ﹤0.01% 2887
2023
Q2 		$374K Buy
+114,085
New +$387K ﹤0.01% 2984
2021
Q2 		– Sell
-170,026
Closed -$683K – 3492
2021
Q1 		$683K Sell
170,026
-5,553
-3% -$18.4K ﹤0.01% 3014
2020
Q4 		$1.17M Buy
175,579
+4,897
+3% +$22.8K ﹤0.01% 2748
2020
Q3 		$980K Sell
170,682
-32,593
-16% -$218K ﹤0.01% 2704
2020
Q2 		$1.5M Buy
+203,275
New +$951K ﹤0.01% 2456

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Nuveen's OVID Position: Q2 2025 in Review

Nuveen sold out of Ovid Therapeutics (OVID) in Q2 2025, closing a stake of 119,113 shares — an estimated $37.2K sold.

Nuveen first reported a position in OVID in Q2 2020 and held it in 12 quarters. The position peaked at $1.5M in Q2 2020. 71 funds tracked by Wall St. Rank hold OVID as of Q2 2025.

  • Nuveen reported no remaining Ovid Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Nuveen sold 119,113 Ovid Therapeutics shares in Q2 2025, an estimated $37.2K.
  • Nuveen first reported a position in Ovid Therapeutics in Q2 2020 and held it in 12 quarters.
  • Nuveen's Ovid Therapeutics position peaked at $1.5M in Q2 2020.
  • 71 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2025.

Based on Nuveen's 13F filing for Q2 2025, filed 12 Aug 2025.